By Dan GartenbergBloomberg, September 13 (–)–The U.S. Food and Drug Administration, which is supposed to be the regulator of prescription drugs, has been too cozy with big pharmaceutical companies to get the most out of its enormous and ever-expanding research programs.
The FDA recently gave Big Pharma a $10 billion loan guarantee, and the agency has also agreed to help with its research program.
The loan guarantees and the research programs will go toward developing new medicines and drugs to treat chronic diseases and conditions, but there’s no guarantee that the FDA will get the full value out of those investments, which are backed by a variety of special interest groups.
For instance, the loan guarantee was approved because Big Pharma is a major player in the new drug industry, according to industry sources, including drug makers Pfizer, Cephalon and Sanofi.
In fact, the FDA has already been forced to take big pharmaceuticals to court over the drug safety and efficacy of a few of its drugs, including EpiPen and OxyContin, even as it has been unable to do much to save the millions of Americans who rely on those drugs.
In 2014, the agency announced it would not renew its EpiPens program, which has cost taxpayers nearly $1 billion since it was first launched in 2013.
A year later, the company appealed that decision and the case is still pending.
The agency has a number of other programs, including a new one aimed at helping drug companies develop more efficient ways of delivering medications to patients, but the biggest impact of all of them is that they allow Big Pharma to control FDA decisions.
The Drug Enforcement Administration, for instance, was already barred from funding research into new and novel drugs because of its ties to Big Pharma.
In 2016, the Drug Enforcement Agency was also banned from funding drugs and devices that could be used to make prescription drugs more effective or safer.
This year, the DEA was allowed to continue funding drugs to be used in the United States.
But the agency cannot fund research that might help companies develop new drugs.
The funding was designed to help Big Pharma keep its monopoly over drug production and distribution.
For years, Big Pharma had been able to use its massive patent portfolio to block out competition, which allowed it to lock down access to new drugs by creating monopolies and squeezing out competitors.
But since 2009, when President Obama announced a crackdown on drug monopolies, Big Pharma has been increasingly challenging Big Pharma’s monopoly over the production and sale of drugs.
Last year, it sued the FDA, which it believed violated its own laws by blocking Big Pharma from making more efficient and safer medicines.
The Supreme Court has recently held that the law’s prohibition on monopolies does not apply to Big Pharmaceuticals because it’s a different type of monopoly, one that the government has no business interfering with.
But the FDA and other agencies are still taking Big Pharma at its word that it doesn’t have a monopoly on drug development, and they are increasingly relying on Big Pharma as a negotiating partner.
In a report last year, The Brookings Institution found that Big Pharma spent nearly $8 billion to lobby the government in 2016.
Big Pharma lobbyists paid a combined $6.2 million to the U.K. and U.A.E. for that work, and that money helped convince the British government to grant Big Pharma access to its research funding.
As. also spent more than $2.2 billion on Big Pharms lobbying during the same period.
Big Pharma spent more money lobbying in 2017 than it did in all of 2016, according a Brookings analysis of federal lobbying disclosures, and it’s spending more money than it’s spent on lobbying in any other year since the 2016 elections.
While the FDA does not have any lobbying expenses, the bureau’s spending on lobbying, which includes its own staff, is expected to grow by nearly $5 million to $7.5 million by 2020.
And Big Pharma has made clear it will continue to be a thorn in the side of the FDA even if it does get its wish to be able to control its drug development.
In an interview with CNNMoney in May, Dr. David Altman, a professor of medical ethics at the University of Pittsburgh School of Medicine, said he believes the FDA could lose the battle to block Big Pharma if it were to start restricting its research programs, saying the FDA’s decision to grant a $1.5 billion loan to BigPharmaceutical could be seen as “a big step backward.”
Altman also said it would be “a good thing if the FDA got out of this business” and became more “hands-off.”
And while Altman said the FDA should not block research funding from BigPharma, he also noted that it has the authority to stop BigPharms from participating in FDA research programs and, for that matter